Costs and savings of investigational drug services

American Journal of Health-System Pharmacy

Volumn 57, Issue 1, 2000, Pages 40-43

  Mcdonagh, Marian S ^a,b,c   Miller, Sheree A ^d   Naden, Ellen ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e Box 356015 ^*

Author keywords

Acquired immunodeficiency syndrome; Administration; Costs; Drugs, investigational; Neoplasms; Pharmaceutical services; Pharmacoeconomics; Pharmacy, institutional, hospital

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; NEW DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CALCULATION; COST CONTROL; DRUG COST; HEALTH CARE COST; HEALTH CARE MANAGEMENT; ONCOLOGY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 0033982588     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.1.40     Document Type: Article

References (16)

1. Rogers RD, Lampasona V, Buchanan EC. The financial impact of investigational drug services. Top Hosp Pharm Manage. 1994; 14(1):60-6.
2. Fink J. Liability threat should be considered when conducting drug investigations. Paper presented at American Pharmaceutical Association Annual Meeting. Washington, DC; 1990 Mar 12.
3. Mehl B. Investigational drug protocols-hidden costs. Hosp Pharm. 1991; 26:459-61.
4. Wermeling DP, Percoro LT, Foster TS. Financial impact of clinical research on a health system. Am J Health-Syst Pharm. 1997; 54:1742-51
5. Gresham C, Allen T. Investigational drug services: management implications. Pharm Times. 1993; 59(Feb):3-12.
6. Hill DP, Browning DA. A perspective on investigational drug management. Top Hosp Pharm Manage. 1993; 13(10):29-36.
7. Rockwell J. Pharmacy based investigational drug services: a national survey. Top Hosp Pharm Manage. 1993; 13(10):1-15.
8. Anandan JV, Isopi MI, Warren AJ. Fee structure for investigational drug studies. Am I Hosp Pharm. 1993; 50:2339-43.
9. Catania HF, Yee WP, Catania PN. Four years' experience with a clinical intervention program: cost avoidance and impact of a clinical coordinator. Am J Hosp Pharm. 1990; 47:2701-5.
10. Mutnick AH, Streba KJ, Peroutka JA et al. Cost savings and avoidance from clinical interventions. Am J Health-Syst Pharm. 1997; 54:392-6.
11. Thomas P, Ross RN, Farrar JR. A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered dose inhaler in the treatment of patients with asthma. Clin Ther. 1996; 18:939-52.
12. Seay RE, Edgren BE, Schilling GC. Cost avoidance using syringe pumps to administer fat emulsion in a neonatal intensive care unit. Am J Hosp Pharm. 1991; 48:1972-4.
13. Wermeling DP. Value of investigational drugs. Am J Hosp Pharm. 1993; 50:1576. Letter.
14. Stolar MH, Gabriel T, Grant KL et al. Pharmacy-coordinated investigational drug services. Am J Hosp Pharm. 1982; 39:432-6.
15. American Society of Health-System Pharmacists. ASHP guidelines on clinical drug research. Am J Health-Syst Pharm. 1998; 55:369-76.
16. Hoffman RP. The use of investigational drugs - JCAHO. Hosp Pharm. 1988; 23: 905-9.